La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Eli Lilly a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Eli Lilly..

Eli Lilly (NYSE:LLY) Azioni, Catena delle Opzioni

Eli Lilly

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Eli Lilly and Co

Wegovy

Health Care

Hims & Hers Health, Inc. Class A Common Stock

HIMS

I giganti farmaceutici celebrano ricavi record. Ma un&#39;insidia nel comportamento dei pazienti minaccia la crescita a lungo termine.

Farmaci anti-obesità: vendite da record, ma c&#39;è un problema

Siegen,,North,Rhine,Westphalia,,,Germany,-,10,11,2023:

Biotech

Large Cap

News

General

La Spagna indaga su presunte irregolarità nella promozione di farmaci dimagranti, con implicazioni per il settore e i consumatori.

La Spagna contro Novo Nordisk: pubblicità occulta per i farmaci dimagranti

Un&#39;importante azienda farmaceutica svela progressi su una nuova soluzione orale per la gestione del peso. Scopri di più.

Perdere peso senza sacrifici? Arriva la pillola orale di Eli Lilly

Liberty Media Corporation - Series A Liberty Live Common Stock

Liberty Live Group

LIBERTY LIVE SERIES B by Liberty Media Corporation

Liberty Media Corporation - Series C Liberty Live Common Stock

Tidal Trust II Defiance Daily Target 2X Long LLY ETF

<a href="https://www.barrons.com/articles/chinese-biotech-obesity-zepbound-lilly-trial-38914a27" title="https://www.barrons.com/articles/chinese-biotech-obesity-zepbound-lilly-trial-38914a27">https://www.barrons.com/articles/chinese-biotech-obesity-zepbound-lilly-trial-38914a27</a>

Global

Reported Earlier: "Lilly's Zepbound Faces a Potential Weight-Loss Rival. It's Made by a Chinese Biotech." - Barron's

Eli Lilly's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) short percent of float has fallen 3.96% since its last report. The company recently reported that it has 7.71 million shares sold short, which is 0.97% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.24 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Eli Lilly Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752602438_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Eli Lilly has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Eli Lilly's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Eli Lilly's peer group average for short interest as a percentage of float is 3.45%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Do Investors Really Feel About Eli Lilly?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$270.00</td>
<td>$663.7K</td>
<td>1.8K</td>
<td>3.3K</td>
</tr>
<tr>
<td>EW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$72.50</td>
<td>$44.4K</td>
<td>6.5K</td>
<td>2.2K</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$22.50</td>
<td>$89.6K</td>
<td>288</td>
<td>427</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/25/25</td>
<td>$800.00</td>
<td>$45.5K</td>
<td>194</td>
<td>213</td>
</tr>
<tr>
<td>TEVA</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$12.00</td>
<td>$56.2K</td>
<td>5.4K</td>
<td>130</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$70.00</td>
<td>$128.7K</td>
<td>1.3K</td>
<td>91</td>
</tr>
<tr>
<td>TEM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/29/25</td>
<td>$59.00</td>
<td>$28.0K</td>
<td>2</td>
<td>56</td>
</tr>
<tr>
<td>BBIO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$40.00</td>
<td>$28.1K</td>
<td>1.6K</td>
<td>42</td>
</tr>
<tr>
<td>TMO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$340.00</td>
<td>$59.2K</td>
<td>170</td>
<td>31</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$360.00</td>
<td>$25.0K</td>
<td>159</td>
<td>23</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option sweep that happens to be bullish, expiring in 185 day(s) on January 16, 2026. This event was a transfer of 299 contract(s) at a $270.00 strike. This particular put needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $663.7K, with a price of $2220.0 per contract. There were 1803 open contracts at this strike prior to today, and today 3308 contract(s) were bought and sold. 
• Regarding EW (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>), we observe a call option trade with bullish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 67 contract(s) at a $72.50 strike. The total cost received by the writing party (or parties) was $44.4K, with a price of $664.0 per contract. There were 6508 open contracts at this strike prior to today, and today 2208 contract(s) were bought and sold. 
• Regarding JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we observe a put option trade with bearish sentiment. It expires in 31 day(s) on August 15, 2025. Parties traded 427 contract(s) at a $22.50 strike. The total cost received by the writing party (or parties) was $89.6K, with a price of $210.0 per contract. There were 288 open contracts at this strike prior to today, and today 427 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bearish sentiment. It expires in 10 day(s) on July 25, 2025. Parties traded 50 contract(s) at a $800.00 strike. The total cost received by the writing party (or parties) was $45.5K, with a price of $910.0 per contract. There were 194 open contracts at this strike prior to today, and today 213 contract(s) were bought and sold. 
• Regarding TEVA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TEVA#NYSE">TEVA</a>), we observe a call option trade with neutral sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 130 contract(s) at a $12.00 strike. The total cost received by the writing party (or parties) was $56.2K, with a price of $433.0 per contract. There were 5421 open contracts at this strike prior to today, and today 130 contract(s) were bought and sold. 
• Regarding NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we observe a call option trade with bullish sentiment. It expires in 338 day(s) on June 18, 2026. Parties traded 132 contract(s) at a $70.00 strike. The total cost received by the writing party (or parties) was $128.7K, with a price of $975.0 per contract. There were 1300 open contracts at this strike prior to today, and today 91 contract(s) were bought and sold. 
• For TEM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), we notice a call option trade that happens to be neutral, expiring in 45 day(s) on August 29, 2025. This event was a transfer of 50 contract(s) at a $59.00 strike. The total cost received by the writing party (or parties) was $28.0K, with a price of $560.0 per contract. There were 2 open contracts at this strike prior to today, and today 56 contract(s) were bought and sold. 
• For BBIO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBIO#NASDAQ">BBIO</a>), we notice a call option sweep that happens to be neutral, expiring in 31 day(s) on August 15, 2025. This event was a transfer of 35 contract(s) at a $40.00 strike. This particular call needed to be split into 5 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $805.0 per contract. There were 1699 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding TMO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>), we observe a put option trade with bullish sentiment. It expires in 549 day(s) on January 15, 2027. Parties traded 25 contract(s) at a $340.00 strike. The total cost received by the writing party (or parties) was $59.2K, with a price of $2370.0 per contract. There were 170 open contracts at this strike prior to today, and today 31 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bullish sentiment. It expires in 66 day(s) on September 19, 2025. Parties traded 18 contract(s) at a $360.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $1390.0 per contract. There were 159 open contracts at this strike prior to today, and today 23 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more news on unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

BBIO

JANX

TEVA

10 Health Care Stocks Whale Activity In Today's Session

Bank of America (BofA) Securities updated the earnings model for Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). The company&nbsp;will announce second-quarter 2025 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b46095809/pfizer-invites-public-to-view-and-listen-to-webcast-of-august-5-conference-call-with-analysts" rel="noreferrer noopener">earnings on August 5</a>.
According to data from <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a>, analysts estimate adjusted earnings of 57 cents per share on sales of $13.41 billion.
In the second quarter, total revenue decreased by less than 1%, and earnings per share remained unchanged.
Analysts also expect revenue and EPS to stay within 1% of previous forecasts. Revenue will likely decline by a low single-digit percentage in the latter part of the 2020s, they say. This is mainly due to Vyndaqel and Ibrance&#8217;s earlier-than-expected loss of exclusivity.
Read Next: <a href="https://www.benzinga.com/news/legal/25/07/46364944/pfizer-sanofi-find-relief-as-delaware-top-court-rejects-zantac-expert-testimony" target="_blank" rel="noreferrer noopener">Pfizer, Sanofi Find Relief As Delaware Top Court Rejects Zantac Expert Testimony</a>
EPS is also expected to shift up or down by a low single-digit percentage, depending on the year.
BofA maintains the <a target="_blank" href="https://www.benzinga.com/quote/PFE/analyst-ratings" rel="noreferrer noopener">price forecast of $27</a> with a Neutral rating using a 9x P/E multiple on updated 2025 EPS.
Pfizer&#8217;s stock is trading at a price-to-earnings ratio of about 8–9 times its expected 2025 earnings. That&#8217;s lower than the peer average of around 12 times, excluding Eli Lilly &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
It also offers a high dividend yield of around 7%, which may help prevent the share price from falling further. However, the long-term outlook is less certain due to upcoming patent expirations and increased competition, which could result in slower-than-average growth.
Pfizer expects its 2025 sales to decline by about $1 billion due to changes under the Inflation Reduction Act (IRA) Part D reform. The company anticipates a $500 million increase in revenue from more patients using its drugs, thanks to lower out-of-pocket costs. However, this is offset by a $1.5 billion loss due to increased costs in the catastrophic phase of Medicare Part D.
Cheaper options (i.e. Eliquis) may benefit from certain reforms more than expensive drugs because the coverage gap is being removed.
In the first quarter of 2025, Pfizer says it already felt a negative impact of around $650 million compared to the same period in 2024, due to higher discount requirements for drugmakers.
Price Action: PFE stock is down 0.64% at $25.49 at the last check on Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46396808/wolfspeed-wolf-stock-resumes-rally-amid-restructuring-optimism" target="_blank" rel="noreferrer noopener">Wolfspeed (WOLF) Stock Resumes Rally Amid Restructuring Optimism</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Guidance

Analyst Ratings

Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook

<figure class="wp-block-image aligncenter size-large"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-1024x683.jpg" alt="" class="wp-image-15723" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-1024x683.jpg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-300x200.jpg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1-768x512.jpg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214706/Top-Image-1.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<h2 class="wp-block-heading">Follow-Up: Sana Biotechnology</h2>
6-Month Data, +150 % Rally, and Morgan Stanley's New Overweight Call
In a public <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">post </a>in May, I wrote about Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>), a biotech that has developed a potential cure for type 1 diabetes. Here's an update on developments since.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">1. Quick Recap of the May 19 Thesis</h3>
<ul class="wp-block-list">
<li>Functional-cure potential.&nbsp;Sana's hypo-immune (HIP) edits let donor islet cells make insulin without triggering rejection—no immunosuppression required.</li>
<li>Moat = immune stealth.&nbsp;Removing MHC I/II and adding "don't-eat-me" CD47 is the core advantage.</li>
<li>Industry disruption.&nbsp;If HIP-edited, stem-cell–derived islets (program SC451) scale, legacy diabetes franchises at&nbsp;Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>),&nbsp;Eli Lilly and Co.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>),&nbsp;DexCom, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>),&nbsp;Insulet Corporation&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PODD#NASDAQ">PODD</a>), etc., may be at risk.</li>
</ul>
(See <a href="https://www.benzinga.com/general/biotech/25/05/45498697/the-end-of-the-diabetes-industry-this-small-cap-could-upend-the-business-models-of-pharma-giants">original </a>post for full details.)
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">2. Stock Performance Since the Post</h3>
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="740" height="151" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13.png" alt="" class="wp-image-15724" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13.png 740w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214746/image-13-300x61.png 300w" sizes="(max-width: 740px) 100vw, 740px" /></figure>
In under eight weeks, SANA has&nbsp;nearly tripled, reflecting a shift from speculative promise to emerging proof-of-concept.
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">3. Six-Month Human Data (June 23)</h3>
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow">"Cells survived, secreted insulin, and responded to meals&nbsp;six months&nbsp;after transplant—without immunosuppression&nbsp;and with&nbsp;no safety issues."&nbsp;<a href="https://www.globenewswire.com/news-release/2025/06/23/3103540/0/en/Sana-Biotechnology-Announces-Positive-Six-Month-Clinical-Results-from-Type-1-Diabetes-Study-of-Islet-Cell-Transplantation-Without-Immunosuppression.html">GlobeNewswire</a>
</blockquote>
Why it matters
<ul class="wp-block-list">
<li>Durability:&nbsp;Continued C-peptide production and meal-stimulated spikes confirm functional beta-cell activity.</li>
<li>Immune evasion:&nbsp;Persistent graft survival validates HIP edits.</li>
<li>Safety:&nbsp;No cell- or procedure-related adverse events.</li>
<li>Path forward:&nbsp;Larger dose-escalation cohorts; IND for stem-cell version (SC451) targeted for 2026.</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">4. Morgan Stanley Joins the Bull Camp (July 2)</h3>
<ul class="wp-block-list">
<li>Initiation:&nbsp;Overweight&nbsp;rating,&nbsp;$12 price target&nbsp;(~3× Friday's close).</li>
<li>Rationale: Six- and 12-week human data "de-risk the platform"; broad cell-engineering pipeline offers additional upside. Investing.com</li>
</ul>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">5. What Could Move the Stock Next</h3>
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Catalyst</th>
<th>Expected Timing</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Additional patients dosed</td>
<td>2H 2025 – 1H 2026</td>
<td>Reproducibility &amp; dose-response</td>
</tr>
<tr>
<td>Peer-review / ADA + IPITA presentations</td>
<td>2025 conf. season</td>
<td>External validation</td>
</tr>
<tr>
<td>SC451 IND filing</td>
<td>2026</td>
<td>Scalable, off-the-shelf therapy</td>
</tr>
<tr>
<td>Non-dilutive partnerships or grants</td>
<td>Anytime</td>
<td>Cash-burn mitigation</td>
</tr>
</tbody>
</table>
</figure>
<hr class="wp-block-separator has-alpha-channel-opacity" />
<h3 class="wp-block-heading">6. Bottom Line</h3>
<ul class="wp-block-list">
<li>Data + Duration:&nbsp;The six-month update converts "interesting science" into early evidence of&nbsp;durable clinical benefit.</li>
<li>Momentum:&nbsp;A ~150 % rally since May 19 shows the market is starting to price in that shift.</li>
<li>Institutional validation:&nbsp;Morgan Stanley's fresh&nbsp;Overweight&nbsp;adds credibility—and a higher-quality buyer base.</li>
</ul>
If you sized SANA small after the May post, the thesis is tracking; consider letting winners run while watching for pullbacks to add. New capital? Size cautiously—it's still a single-patient read-out—but the upside/skew remains attractive as more data rolls in.
And if you're long legacy diabetes treatment companies, consider hedging them. Although Sana is aiming to cure T1 diabetes, its treatment could potentially impact the market for management of some forms of T2 diabetes as well (e.g., insulin therapy). As a reminder, you can use&nbsp;<a href="https://portfolioarmor.com/">Portfolio Armor's website</a>&nbsp;or&nbsp;<a href="https://apps.apple.com/us/app/portfolio-armor/id394951144">iPhone app</a>&nbsp;to scan for cost-effective hedges.
<figure class="wp-block-image size-large"><a href="https://apps.apple.com/us/app/portfolio-armor/id394951144"><img loading="lazy" decoding="async" width="1024" height="683" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-1024x683.jpeg" alt="" class="wp-image-15725" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-1024x683.jpeg 1024w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-300x200.jpeg 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1-768x512.jpeg 768w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12214805/PA-JPEG-1.jpeg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
And if you want a heads up when we place our next trade, you can subscribe to the Portfolio Armor trading Substack below.&nbsp;
<figure class="wp-block-image size-full"><a href="https://blog.portfolioarmor.com/"><img loading="lazy" decoding="async" width="581" height="372" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1.jpg" alt="" class="wp-image-15726" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1.jpg 581w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/07/12215355/Widget-1-300x192.jpg 300w" sizes="(max-width: 581px) 100vw, 581px" /></a></figure>

Equities

Opinion

DXCM

PODD

SANA

How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes

On CNBC's &#8220;<a href="https://www.benzinga.com/topic/mad-money-lightning-round">Mad Money Lightning Round</a>,&#8221; Jim Cramer said Rocket Lab Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) is a buy, adding that it is &#8220;one of the hottest stocks in the universe.&#8221;
On June 30, the space-tech company notched its fastest launch turnaround ever, completing its 68th Electron mission and signaling a new era of rapid-response rocket deployment.
He also recommended buying Huntington Ingalls Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HII#NYSE">HII</a>).
Supporting his view, TD Cowen analyst Gautam Khanna, on July 10, upgraded Huntington Ingalls <a href="https://www.benzinga.com/quote/HII/analyst-ratings">from Hold to Buy and raised the price target from $250 to $300.</a>
&#8220;This thing is just a coiled spring when we get the new numbers,&#8221; Cramer said when asked about Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>). &#8220;There are many big studies coming down the pipe.&#8221;
Guggenheim analyst Seamus Fernandez, on July 11, maintained Eli Lilly with a Buy and raised the price target from $936 to $942.
When asked about TSS, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSSI#NASDAQ">TSSI</a>), he said, &#8220;That's a pretender. We want to be in CoreWeave if we're going to go there.&#8221;
On the earnings front, TSS, on May 15, reported a year-over-year increase in first-quarter revenue results.
Cramer recommended not buying Conagra Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAG#NYSE">CAG</a>), saying it's a &#8220;very tough situation.&#8221;
The company, on July 10, reported adjusted earnings per share of 56 cents, missing the analyst consensus estimate of 58 cents. Quarterly net sales of $2.78 billion, missed the Street view of $2.83 billion.
Cramer recommended buying NXP Semiconductors N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) on Monday morning.
Lending support to his choice, KeyBanc, on July 8, maintained an Overweight rating and raised the price target from $240 to $275.
Power Solutions International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIX#NASDAQ">PSIX</a>) is an &#8220;amazing stock, it's not even that expensive,&#8221; Cramer said.
Supporting his view, the company, on May 8, reported a year-over-year increase in first-quarter financial results.
Price Action:
<ul class="wp-block-list">
<li>Huntington Ingalls Industries shares gained 0.03% to settle at $258.18 on Friday.</li>
<li>Rocket Lab shares fell 0.2% to close at $39.03.</li>
<li>TSS shares gained 3.3% to settle at $26.46 on Friday.</li>
<li>Eli Lilly shares gained 0.3% to close at $793.01.</li>
<li>Conagra Brands shares fell 0.5% to settle at $19.40 on Friday.</li>
<li>NXP Semiconductors shares fell 1.8% to close at $228.92.</li>
<li>Power Solutions International shares gained 5.3% to settle at $72.02.</li>
</ul>
Read Next:<a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month"> </a>
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/07/46364472/top-3-real-estate-stocks-that-may-fall-off-a-cliff-this-month">Top 3 Real Estate Stocks That May Fall Off A Cliff This Month</a></li>
</ul>
Image: Shutterstock

Long Ideas

SPACE

Markets

Media

NXPI

PSIX

RKLB

TSSI

This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Says

Deep-pocketed investors have adopted a bearish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 89 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 41% leaning bullish and 44% bearish. Among these notable options, 25 are puts, totaling $2,353,651, and 64 are calls, amounting to $51,869,753.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $500.0 to $1040.0 for Eli Lilly over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Eli Lilly stands at 1044.75, with a total volume reaching 30,575.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Eli Lilly, situated within the strike price corridor from $500.0 to $1040.0, throughout the last 30 days.
<h3>Eli Lilly Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752264144_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$86.85</td>
<td>$86.25</td>
<td>$86.85</td>
<td>$790.00</td>
<td>$390.8K</td>
<td align="right">505</td>
<td align="right">101</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$86.0</td>
<td>$82.1</td>
<td>$86.0</td>
<td>$860.00</td>
<td>$387.0K</td>
<td align="right">82</td>
<td align="right">135</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$205.8</td>
<td>$203.5</td>
<td>$203.5</td>
<td>$580.00</td>
<td>$366.3K</td>
<td align="right">30</td>
<td align="right">18</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$82.55</td>
<td>$82.45</td>
<td>$82.45</td>
<td>$740.00</td>
<td>$197.7K</td>
<td align="right">133</td>
<td align="right">28</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>09/19/25</td>
<td>$53.65</td>
<td>$52.4</td>
<td>$52.4</td>
<td>$790.00</td>
<td>$146.7K</td>
<td align="right">400</td>
<td align="right">69</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 2,047,296, the LLY's price is up by 0.2%, now at $792.27. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 27 days.</li>
</ul>
<h3>What The Experts Say On Eli Lilly</h3>
3 market experts have recently issued ratings for this stock, with a consensus target price of $1004.33.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on Eli Lilly with a target price of $1135. 
&#x2A; An analyst from Guggenheim has decided to maintain their Buy rating on Eli Lilly, which currently sits at a price target of $942. 
&#x2A; Reflecting concerns, an analyst from Guggenheim lowers its rating to Buy with a new price target of $936.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Market Whales and Their Recent Bets on LLY Options

In the latest quarter, 7 analysts provided ratings for Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $952.29, with a high estimate of $1135.00 and a low estimate of $700.00. Observing a downward trend, the current average is 8.26% lower than the prior average price target of $1038.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1752242428_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Eli Lilly. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$942.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Terence Flynn</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$1135.00</td>
<td>$1133.00</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Maintains</td>
<td>Buy</td>
<td>$936.00</td>
<td>$936.00</td>
</tr>
<tr>
<td>Trung Huynh</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$1050.00</td>
<td>$1100.00</td>
</tr>
<tr>
<td>Rajesh Kumar</td>
<td>HSBC</td>
<td>Lowers</td>
<td>Reduce</td>
<td>$700.00</td>
<td>$1150.00</td>
</tr>
<tr>
<td>Carter Gould</td>
<td>Cantor Fitzgerald</td>
<td>Announces</td>
<td>Overweight</td>
<td>$975.00</td>
<td>-</td>
</tr>
<tr>
<td>Seamus Fernandez</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$928.00</td>
<td>$973.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Eli Lilly. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Eli Lilly compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Eli Lilly's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Eli Lilly's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/LLY/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Eli Lilly analyst ratings.</a>
<h2>About Eli Lilly</h2>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Eli Lilly: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Over the 3M period, Eli Lilly showcased positive performance, achieving a revenue growth rate of 45.17% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 21.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Eli Lilly's ROE excels beyond industry benchmarks, reaching 18.42%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Eli Lilly's ROA stands out, surpassing industry averages. With an impressive ROA of 3.28%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.44, caution is advised due to increased financial risk.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts

Guggenheim analyst Seamus Fernandez maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Buy and raises the price target from $936 to $942.

Price Target

Guggenheim Maintains Buy on Eli Lilly, Raises Price Target to $942

While President Donald Trump's proposed 200% tariffs on pharmaceutical imports could potentially squeeze the profit margins, this stock is poised to &#8220;benefit&#8221; from the levies. 
What Happened: Trump announced on Tuesday that the pharma tariffs, part of a Section 232 investigation launched in April, are expected to be detailed by month's end, with a grace period of "about a year, year and a half" before implementation.
Barclays cautioned that a 200% tariff would "inflate production costs, compress profit margins, and risk supply chain disruptions.&#8221; However, the delay offers little relief, <a href="https://www.cnbc.com/2025/07/11/trump-200percent-pharma-tariffs-threaten-to-push-up-drug-prices-hit-margins.html">as</a> CNBC reported, quoting UBS analysts that it's "insufficient time" for firms to relocate manufacturing, typically a four-to-five-year process. 
But despite the potential negative impact on pharma companies, Louis Navellier told <a href="https://www.benzinga.com">Benzinga </a>that Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is &#8220;expected to benefit from tariffs on pharmaceutical imports, since the company has been boosting its domestic manufacturing.&#8221;
Additionally, Thomas Shipp, head of equity research at LPL Financial, told <a href="https://pro.benzinga.com/dashboard">Benzinga</a> that Lilly's attempt to try &#8220;to avoid PBMs,&#8221; exemplified by its direct-to-consumer model, &#8216;LillyDirect&#8217; in partnership with Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), positions it to bypass traditional pharmacy benefit managers, enhancing its resilience against tariff-related disruptions.
See Also: <a href="https://www.benzinga.com/markets/equities/25/07/46361386/bitcoin-breaches-118k-but-these-btc-mining-firms-are-still-priced-like-its-at-58k-heres-how-these-mining-stocks-could-explode">Bitcoin Breaches $118K, But These BTC Mining Firms Are Still Priced Like It&#8217;s At $58K: Here&#8217;s How These Mining Stocks Could Explode</a>
Why It Matters: Additionally, Lilly's strategic moves, including a $1.3 billion <a href="https://www.benzinga.com/m-a/25/06/45970361/eli-lilly-expands-into-gene-editing-with-verve-therapeutics-acquisition">acquisition of Verve Therapeutics</a>, signal its focus on innovation and U.S.-based growth. 
Ark Research noted that this acquisition validates gene-editing therapies for cardiovascular disease, a market with "trillions of dollars" in potential, as Lilly scales solutions like PCSK9-targeting therapies that reduce LDL-C by up to 69%.
Apart from the effects on the profitability of pharmaceutical companies, according to PhRMA, the tariffs could raise U.S. drug prices by $51 billion annually with just a 25% tariff levy, potentially increasing costs by 12.9%.
Price Action: Eli Lilly stock declined 0.078% in premarket on Friday; it was up 1.62% on a year-to-date basis but down by 15.36% over the last year.
Benzinga Edge Stock Rankings shows that LLY had a weak momentum and value ranking; however, its growth and quality metrics were very strong. The details of all the important indicators are <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-4/#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">available here</a>.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="163" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png" alt="" class="wp-image-981662" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-1024x163.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-300x48.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge-768x122.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/11071005/LLY-edge.png 1039w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
These are some pharma stocks and ETFs that could be impacted as Trump warned on Tuesday that long-awaited industry-wide tariffs would be announced "very soon".
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma Stocks</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>Eli Lilly And Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>)</td>
<td>1.62%</td>
<td>-15.36%</td>
</tr>
<tr>
<td>AbbVie Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>)</td>
<td>8.67%</td>
<td>14.77%</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>)</td>
<td>-14.56%</td>
<td>19.07%</td>
</tr>
<tr>
<td>Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>)</td>
<td>-21.73%</td>
<td>-48.18%</td>
</tr>
<tr>
<td>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)</td>
<td>-3.12%</td>
<td>-10.05%</td>
</tr>
<tr>
<td>Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>)</td>
<td>24.66%</td>
<td>63.70%</td>
</tr>
<tr>
<td>Merck &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>)</td>
<td>-15.28%</td>
<td>-34.85%</td>
</tr>
<tr>
<td>Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>)</td>
<td>15.85%</td>
<td>-7.60%</td>
</tr>
<tr>
<td>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>)</td>
<td>9.49%</td>
<td>5.34%</td>
</tr>
</tbody>
</table>
</figure>
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Pharma ETFs</td>
<td>YTD Performance</td>
<td>One Year Performance</td>
</tr>
<tr>
<td>VanEck Pharmaceutical ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPH#NASDAQ">PPH</a>)</td>
<td>3.50%</td>
<td>-3.73%</td>
</tr>
<tr>
<td>iShares US Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>)</td>
<td>3.15%</td>
<td>-0.88%</td>
</tr>
<tr>
<td>Invesco Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJP#NYSE">PJP</a>)</td>
<td>0.68%</td>
<td>-0.49%</td>
</tr>
<tr>
<td>SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>)</td>
<td>-0.16%</td>
<td>2.31%</td>
</tr>
<tr>
<td>KraneShares MSCI All China Health Care Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KURE#NYSE">KURE</a>)</td>
<td>25.74%</td>
<td>30.34%</td>
</tr>
<tr>
<td>First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXH#NASDAQ">FTXH</a>)</td>
<td>-1.00%</td>
<td>-4.29%</td>
</tr>
<tr>
<td>Direxion Daily Pharmaceutical &amp; Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PILL#NYSE">PILL</a>)</td>
<td>-14.12%</td>
<td>-14.74%</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/politics/25/07/46336115/as-trump-calls-for-3-percentage-point-rate-cut-too-late-jerome-powell-to-resign-june-fed-minutes-sh">As Trump Calls For 3-Percentage Point Rate Cut, &#8216;Too Late&#8217; Jerome Powell To Resign, June Fed Minutes Show &#8216;Uncertainty&#8217; Reigns Supreme</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Shuttertsock

ABBV

AMGN

AMZN

FTXH

GILD

iShares Dow Jones US Pharmaceuticals Index Fund

KURE

PILL

Merrill Lynch Pharmaceutical HOLDRs Trust

REGN

Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

Morgan Stanley analyst Terence Flynn maintains Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) with a Overweight and raises the price target from $1133 to $1135.

Morgan Stanley Maintains Overweight on Eli Lilly, Raises Price Target to $1135

Deep-pocketed investors have adopted a bullish approach towards Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 40 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 55% leaning bullish and 25% bearish. Among these notable options, 6 are puts, totaling $330,318, and 34 are calls, amounting to $5,397,011.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $370.0 to $990.0 for Eli Lilly over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In terms of liquidity and interest, the mean open interest for Eli Lilly options trades today is 321.08 with a total volume of 4,088.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Eli Lilly's big money trades within a strike price range of $370.0 to $990.0 over the last 30 days.
<h3>Eli Lilly Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1752163269_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th align="right">Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$169.0</td>
<td>$169.0</td>
<td>$169.0</td>
<td>$750.00</td>
<td>$1.6M</td>
<td align="right">617</td>
<td align="right">98</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$168.85</td>
<td>$167.0</td>
<td>$168.85</td>
<td>$750.00</td>
<td>$472.7K</td>
<td align="right">617</td>
<td align="right">164</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$168.85</td>
<td>$167.0</td>
<td>$168.85</td>
<td>$750.00</td>
<td>$320.8K</td>
<td align="right">617</td>
<td align="right">183</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>10/17/25</td>
<td>$49.5</td>
<td>$49.15</td>
<td>$49.5</td>
<td>$830.00</td>
<td>$297.0K</td>
<td align="right">182</td>
<td align="right">102</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$169.0</td>
<td>$168.85</td>
<td>$169.0</td>
<td>$750.00</td>
<td>$287.3K</td>
<td align="right">617</td>
<td align="right">126</td>
</tr>
</tbody>
</table>

<h3>About Eli Lilly</h3>
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
<h3>Where Is Eli Lilly Standing Right Now?</h3>
<ul>
<li>With a volume of 1,089,317, the price of LLY is up 1.15% at $795.98. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 28 days.</li>
</ul>
<h3>Professional Analyst Ratings for Eli Lilly</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $936.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Guggenheim has revised its rating downward to Buy, adjusting the price target to $936. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Eli Lilly, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

This Is What Whales Are Betting On Eli Lilly

Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) is set to release its second-quarter earnings on August 7. According to&nbsp;<a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">Benzinga Pro</a> data,&nbsp;analysts are anticipating adjusted earnings of $5.56 per share and sales of $14.4 billion.
Expectations are slightly higher for the quarter, primarily driven by the strong performance of its obesity drug, Zepbound. The pharmaceutical giant, a dominant player in the incretin/GLP-1 drug market for obesity and diabetes, continues to draw investor attention with its robust pipeline and long-term growth prospects.
<h2 class="wp-block-heading">Analyst Adjustments and Forecasts</h2>
Ahead of the earnings release, Bank of America Securities (BofA) has made minor adjustments to its earnings model for Eli Lilly.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/fda/25/07/46319441/fda-approves-new-dosing-schedule-for-eli-lillys-kisunla-in-alzheimers-treatment" rel="noreferrer noopener">FDA Approves New Dosing Schedule For Eli Lilly&#8217;s Kisunla In Alzheimer&#8217;s Treatment</a>
BofA analyst Tim Anderson specifically noted a slight, low single-digit percentage increase in <a target="_blank" href="https://www.benzinga.com/earnings" rel="noreferrer noopener">second-quarter revenue</a> and EPS forecasts, primarily driven by stronger anticipated sales of Zepbound.
Looking further out, the analyst updated full-year projections, expecting total revenue to rise by 1% and 0.4% in 2025, with EPS growing by 1.9% in 2025 but experiencing a slight dip of 0.7% in 2026.
Beyond 2026, revenue and EPS projections largely remain consistent. Importantly, long-term forecasts for Lilly&#8217;s key products, Mounjaro, Zepbound, orforglipron, and retatrutide, have not seen significant revisions.
<h2 class="wp-block-heading">BofA Maintains Buy Rating</h2>
BofA maintains a Buy rating on Eli Lilly, with a <a target="_blank" href="https://www.benzinga.com/quote/LLY/analyst-ratings" rel="noreferrer noopener">price forecast of $1,000</a>. This reflects the firm&#8217;s view of Lilly&#8217;s exceptional and sustainable growth potential compared to its peers, at what is considered a reasonable valuation.
The core focus of the company remains its incretin/GLP-1 drugs for obesity and diabetes, a market where Lilly is expected to maintain a leading position in the foreseeable future alongside one other top company.
<h2 class="wp-block-heading">Key Focus Areas for the Earnings Call</h2>
The earnings call will focus on several key areas. Broader concerns around U.S. drug pricing changes, including the &#8216;most favored nation&#8217; proposal and possible pharma-related tariffs under Section 232, are expected to be discussed.
Important upcoming clinical trial results, such as tirzepatide&#8217;s SURPASS-CVOT, orforglipron&#8217;s ATTAIN-1, and Novo Nordisk A/S&#8217; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) REDEFINE-4, will also be a point of interest.
Performance updates on major products, especially Mounjaro and Zepbound, will be closely watched. Additionally, early launch progress for new drugs like Kisunla for Alzheimer&#8217;s and Ebglyss for eczema will be highlighted.
Price Action: LLY stock is trading higher by 0.82% to $784.07 at last check Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46324159/why-china-automotive-systems-stock-is-gaining-on-wednesday" target="_blank" rel="noreferrer noopener">Why China Automotive Systems Stock Is Gaining On Wednesday</a></li>
</ul>
Photo via Shutterstock

Reiteration

Topics

Zepbound Powers Eli Lilly's Upbeat Q2 Outlook

The U.S. Food and Drug Administration (FDA) has approved a label update with a new recommended titration dosing schedule for Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) Kisunla (donanemab-azbt) once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer&#8217;s disease (AD). The FDA approved the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/39620867/eli-lillys-alzheimers-therapys-broad-label-reflects-regulatory-confidence-in-anti-a" target="_blank" rel="noreferrer noopener">drug in July 2024</a>.
In the <a href="https://www.benzinga.com/general/biotech/24/10/41608511/eli-lilly-says-new-data-can-potentially-provide-path-to-improved-donanemab-profile-by-lower-risk-" target="_blank" rel="noreferrer noopener">TRAILBLAZER-ALZ 6 study</a>, the modified titration schedule significantly reduced the incidence of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) compared to the original dosing schedule at 24 and 52 weeks, while still achieving similar levels of amyloid plaque removal <a href="https://www.benzinga.com/pressreleases/25/07/n46314838/fda-approves-updated-label-for-lillys-kisunla-donanemab-azbt-with-new-dosing-in-early-symptomatic-" target="_blank" rel="noreferrer noopener">and P-tau217 reduction</a>.
The new recommended dosing regimen involves a more gradual titration.
ARIA-E is a side effect of amyloid plaque-targeting therapies, including Kisunla. ARIA-E is usually asymptomatic, although serious and fatal events can occur.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44175948/alzheimers-drugs-from-eli-lilly-and-biogen-still-deemed-too-costly-for-nhs-funding" rel="noreferrer noopener">Alzheimer&#8217;s Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding</a>
The new dosing recommendation differs from the original dosing by shifting a single vial from the first dose to the third dose, delivering the same amount of Kisunla by week 24.
This resulted in lower rates of ARIA-E without compromising Kisunla&#8217;s ability to reduce amyloid plaque or its once-monthly dosing, with the potential for a limited-duration treatment based on amyloid plaque removal to minimal levels.
Key findings from the TRAILBLAZER-ALZ 6 study, which supports this label update, included:
<ul class="wp-block-list">
<li>The results showed that the incidence of ARIA-E was 14% in patients receiving the modified titration regimen compared with 24% for those receiving the original dosing regimen, representing a 41% lower relative risk.</li>
<li>At week 52, the incidence of ARIA-E was 16% in patients receiving the modified titration compared with 25% for those receiving the original dosing regimen, a 35% lower relative risk.</li>
<li>Including asymptomatic radiographic events at week 52, ARIA, ARIA-E, and ARIA-H were observed in 29%, 16%, and 25% of patients receiving the modified titration dosing.</li>
<li>ARIA-E and ARIA-H are different types of amyloid-related imaging abnormalities (ARIA). ARIA with edema is characterized as ARIA-E, and ARIA with hemosiderin deposition is characterized as ARIA-H.</li>
</ul>
Patients on the modified titration experienced a reduction of amyloid plaque and P-tau217 comparable to patients receiving the original dosing regimen.
At 24 weeks, amyloid plaque levels in patients on the modified titration of donanemab in TRAILBLAZER-ALZ 6 were reduced on average by 67% from baseline compared to 69% for patients on the original dosing regimen.
No new adverse reactions were identified in the study, although higher rates of hypersensitivity and infusion-related reactions were observed.
In March, the European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued an opinion that does not recommend Eli Lilly&#8217;s donanemab be granted marketing authorization in early symptomatic Alzheimer&#8217;s disease. Lilly will seek <a href="https://www.benzinga.com/25/03/44544761/european-drug-regulator-gives-thumbs-down-to-eli-lillys-alzheimers-drug-analyst-says-it-is-incremental-win-for-biogen" target="_blank" rel="noreferrer noopener">re-examination by CHMP</a>.
Price Action: LLY stock is up 0.30% at $780 during the premarket session at the last check on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/m-a/25/07/46317822/merck-strikes-10-billion-deal-for-verona-secures-first-in-class-copd-drug" target="_blank" rel="noreferrer noopener">Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug</a></li>
</ul>
Photo: Shutterstock

FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment

The FDA Approves Eli Lilly's Label Update With A New Recommended Titration Dosing Schedule For Kisunla (Donanemab-azbt), Once-monthly Amyloid-targeting Therapy For Adults With Early Symptomatic Alzheimer's Disease

Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) on Tuesday announced that it has submitted an application to the European Medicines Agency (EMA) for approval of a new, higher <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">dose of its obesity treatment</a>, Wegovy (subcutaneous semaglutide 7.2 mg).
The submission is based on clinical data from the STEP UP and STEP UP T2D trials, investigating the efficacy and safety of semaglutide 7.2 mg in adults with obesity in STEP UP, and adults with obesity and type 2 diabetes in STEP UP T2D.
In the STEP UP trial, the <a target="_blank" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916360" rel="noreferrer noopener">new</a> dose of Wegovy (semaglutide 7.2 mg) demonstrated a substantial average weight loss of 21% in people with obesity, with a third of participants losing 25% or more of their body weight compared with placebo.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can't Afford Long-Term Use: ‘Coverage Is Not The Same As Access,' Says Expert</a>
Data also indicated that semaglutide 7.2 mg had a well-tolerated safety profile consistent with semaglutide 2.4 mg and the previous Novo Nordisk semaglutide trials.
Data from&nbsp;clinical trials&nbsp;also point to a slightly higher risk of developing the condition in people taking semaglutide compared with people taking a placebo (a dummy treatment).
In June, EMA's safety committee (PRAC) concluded its review of medicines containing semaglutide following concerns regarding a possible increased risk of developing non-arteritic anterior ischemic optic neuropathy (NAION), an eye condition that may <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">cause vision loss</a>.
After reviewing all available data on NAION with semaglutide, including data from non-clinical studies,&nbsp;clinical trials, post-marketing surveillance and the medical literature,&nbsp;the committee concluded that NAION is a very rare side effect of semaglutide (meaning it may affect up to 1 in 10,000 <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/45814068/novo-nordisks-wegovy-tied-to-increased-risk-of-rare-vision-loss-disorder-european-regulators-say" rel="noreferrer noopener">people taking semaglutide)</a>.
<h2 class="wp-block-heading">Wegovy Vs. Mounjaro</h2>
Novo Nordisk launched Wegovy (semaglutide) in <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/06/46076029/novos-india-move-could-reshape-the-weight-loss-drug-war-with-eli-lilly" rel="noreferrer noopener">India in June to compete</a> with Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
Novo Nordisk told Reuters that Wegovy is available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg doses. The first three will cost 4,336 rupees ($50.7), and the monthly cost will be 17,345 rupees ($201.4), similar to Eli Lilly's Mounjaro.
Some of Novo Nordisk's executives say the company allegedly ignored internal warnings that it was <a target="_blank" href="https://www.benzinga.com/markets/large-cap/25/07/46198535/novo-nordisk-ignored-internal-warnings-on-wegovy-launch-preparedness-report" rel="noreferrer noopener">unprepared to launch Wegovy</a>.
Wegovy, approved in the U.S. in mid-2021, marked a major advancement in obesity treatment and helped Novo generate $46 billion in net profit since then.
But the company has struggled to keep pace with Lilly's Zepbound, which has surpassed Wegovy in weekly new prescriptions this year.
Price Action: NVO stock is up 1.43% at $70.32 at the last check on Tuesday
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/07/46295652/wolfspeed-stock-continues-to-surge-whats-driving-the-momentum" target="_blank" rel="noreferrer noopener">Wolfspeed Stock Continues To Surge: What's Driving The Momentum?</a></li>
</ul>
Photo by Tobias Arhelger via Shutterstock

Eurozone

Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval

WW International, Inc. (WeightWatchers) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WW#NASDAQ">WW</a>) announced on Tuesday&nbsp;the successful completion of its strategic reorganization process.
WeightWatchers implemented a financial reorganization transaction in May to strengthen its financial position and increase investment flexibility. The company <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45239193/weightwatchers-takes-strategic-action-to-eliminate-1-15-billion-of-debt-strengthening-financial-po" rel="noreferrer noopener">eliminated $1.15 billion in debt</a>.
With this improved financial foundation, the company is well equipped to execute its transformation plan, which includes innovating its digital and member experience and accelerating the expansion of <a target="_blank" href="https://www.benzinga.com/topic/weight-loss" rel="noreferrer noopener">its telehealth business</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/25/04/45073094/weightwatchers-integrates-with-eli-lilly-to-expand-access-to-zepbound-stock-skyrockets-110" rel="noreferrer noopener">WeightWatchers Integrates With Eli Lilly To Expand Access To Zepbound, Stock Skyrockets 110%</a>
The company said in a press release in May that the business delivered 57% year-over-year revenue growth in the first quarter of 2025.
As part of this accelerated transformation, WeightWatchers made key leadership appointments. In its SEC <a target="_blank" href="https://www.sec.gov/Archives/edgar/data/105319/000119312525156416/d83528dex991.htm" rel="noreferrer noopener">filing</a> on Tuesday, WeightWatchers said it appointed Dr.&nbsp;Kim Boyd as Chief Medical Officer to lead the company&#8217;s clinical vision, program development, and the integration of science into solutions for members.
&#8220;This is a pivotal moment for WeightWatchers,&#8221; said Tara Comonte, Chief Executive Officer of WeightWatchers. &#8220;With renewed financial strength, an expanded leadership team, and the addition of Dr.&nbsp;Boyd to lead clinical strategy and program innovation, we&#8217;re accelerating our transformation.&#8221;
Looking ahead, WeightWatchers will launch a new program later this year to support women through perimenopause, menopause, and postmenopause.
The offering builds upon WeightWatchers&#8217; existing program by delivering tailored nutritional and behavioral strategies with access to specialized clinical care, coaching, and community. The expansion into women&#8217;s health is a strategic move to address a broader gap in healthcare.
In addition to Dr. Boyd&#8217;s appointment, WeightWatchers has appointed Uta Knablein as Chief Product Officer to lead product strategy across the company&#8217;s expanding weight health platform.
As part of WeightWatchers&#8217; reorganization, a new Board of Directors will guide the company through its next growth phase.
Earlier in July, WeightWatchers announced an <a target="_blank" href="https://corporate.ww.com/news/news-details/2025/WeightWatchers-and-Novo-Nordisk-Expand-Collaboration-to-Improve-Medication-Access-Through-Trusted-Holistic-Model-of-Care/default.aspx" rel="noreferrer noopener">expanded</a> collaboration with Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), which includes increased access to authentic, FDA-approved Wegovy (semaglutide) injection through WeightWatchers Clinic.
Additionally, Novo Nordisk is offering a limited-time savings offer available to WeightWatchers Clinic members. Starting July 1, 2025, eligible cash-pay members can access Wegovy at a reduced price of $299 until&nbsp;July 31, 2025.
In April, WeightWatchers announced a pharmacy integration with Eli Lilly and Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) LillyDirect <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45066438/weightwatchers-streamlines-member-access-to-zepbound-vials-with-lillydirect-pharmacy-provider" rel="noreferrer noopener">pharmacy provider</a>, Gifthealth.
The integration will streamline access to Lilly&#8217;s FDA-approved Zepbound (tirzepatide) single-dose vials for WeightWatchers Clinic members with an on-label prescription from their clinician.
The integration will streamline access to Zepbound by offering a vial format for eligible Zepbound self-pay patients without insurance coverage.
Gifthealth will fulfill on-label prescriptions for Zepbound vials written by board-certified clinicians. WeightWatchers members will receive real-time Rx tracking directly within the WeightWatchers App.
Price Action: WW stock is trading higher by 2.75% to $41.10 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/25/07/46298240/voo-gets-some-love-as-investors-say-no-thanks-to-magnificent-7-stocks" target="_blank" rel="noreferrer noopener">VOO Gets Some Love As Investors Say &#8216;No Thanks&#8217; To Magnificent 7 Stocks</a></li>
</ul>
Photo by shisu_ka via Shutterstock

Movers

WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation

Eli Lilly (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) has outperformed the market over the past 10 years by 12.75% on an annualized basis producing an average annual return of 24.16%. Currently, Eli Lilly has a market capitalization of $693.38 billion. 
Buying $1000 In LLY: If an investor had bought $1000 of LLY stock 10 years ago, it would be worth $8,701.53 today based on a price of $771.99 for LLY at the time of writing.
<h3>Eli Lilly's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1751929214_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today

While multinational pharmaceutical firm Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) represents one of the top drugmakers in the world, that status alone hasn't exempted its equity from underperformance. In the past 52 weeks, LLY stock finds itself down almost 16%. Since the beginning of this year, LLY has barely poked its head above parity. Nevertheless, the statistical winds may point to an eventual recovery which options traders could potentially exploit.
Fundamentally, in the post-pandemic era, sentiment toward Eli Lilly skyrocketed thanks to its <a href="https://www.benzinga.com/news/25/01/42933134/fda-approves-weight-loss-drug-zepbound-for-sleep-apnea-will-insurance-cover-this-1000-per-month-medication">weight-loss drug</a>. In 2023, the U.S. Food and Drug Administration (FDA) approved the Zepbound (tirzepatide), the first prescription medication for treating moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity. An injectable prescription medication that helps adults with other weight-related problems, Zepbound's clinical trials showed promising results.
Thanks to this early success, Eli Lilly and Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) effectively formed a duopoly in the weight-loss market. While this reality contributed to a significant valuation surge, competition started to heat up last year. With major pharmaceuticals like Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Roche Holding Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announcing advancements in the <a href="https://www.benzinga.com/general/biotech/24/07/39849867/exclusive-weight-loss-duopoly-breaks-as-eli-lilly-novo-plummet-market-wont-be-dominated-by-just-2">development of obesity-fighting drugs</a>, LLY stock entered into a frustrating consolidation channel.
Still, with the pharmaceutical giant incurring an extended period of red ink in the market, JPMorgan analyst Chris Schott is essentially making the case that Eli Lilly is undervalued. Specifically, prescriptions for Zepbound and Mounjaro (an injectable <a href="https://www.lilly.com/news/media/media-kits/mounjaro">medicine</a> for adults with type 2 diabetes) are running ahead of expectations in the second quarter. As such, this performance may allow the pharmaceutical to beat and raise guidance throughout 2025.
Even with the <a href="https://www.benzinga.com/content/45261458/is-eli-lilly-a-buy-after-weak-earnings-and-cvs-novo-partnership">formulary change</a> by CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) putting around 200,000 patients at risk of losing access, Schott states that Eli Lilly's market share — which stands at about 70% to 75% of new patients — and strong momentum may help the company easily absorb the impact.
<h2 class="wp-block-heading">Statistical Backdrop Could Point To A Recovery In LLY Stock</h2>
Although the fundamental narrative of LLY stock is intriguing, it may also be a presuppositional leap. Essentially, the conclusion that LLY is undervalued is already embedded in the premise (that the market is not fully pricing in the good news for Eli Lilly).
If one thinks about it, it's an extraordinary claim. LLY stock routinely ranks among the most actively traded securities. That the market is somehow mispricing the pharmaceutical giant is an assertion that requires extraordinary evidence. In my opinion, if such evidence exists, it will likely materialize in the statistical realm as it's the arena that few (if any) analysts venture into.
A significant barrier to statistical analysis of the financial markets is the deployment of continuous scalar signals, such as share price or various valuation ratios. Because these signals are non-stationary, it's difficult (if not outright impossible) to extract meaningful insights based on the frequency of past analogs. Especially for highly traded securities like LLY stock, the measurement metrics constantly fluctuate.
To remedy this problem, we can impose stationarity by converting scalar signals into discrete states. For analyzing securities, converting share price into market breadth or sequences of accumulative and distributive sessions carries significant advantages. First, market breadth is essentially a representation of demand and demand is effectively binary. Second, clusters of binary codes can form distinct behavioral states, which can then serve as past analogs for extracting forward probabilities.
As an example, in the trailing two months, the price action of LLY stock can be interpreted as a "6-4-D" sequence: six up weeks, four down weeks, with a negative trajectory across the 10-week period. Admittedly, this process pancakes LLY's magnitude dynamism into a simple binary code. But the benefit is that this code can be easily segregated into distinct market profiles. From there, we can observe the likelihood of transition from one state to another.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg" alt="" class="wp-image-975331" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-1024x576.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-300x169.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast-768x432.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/07/07142726/LLY-stock-10wk-forecast.jpg 1280w" sizes="(max-width: 1024px) 100vw, 1024px" /><figcaption class="wp-element-caption">Image by author</figcaption></figure>
With the above framework, we can identify that since January 2019, the 6-4-D sequence has materialized 38 times. From past analogs, we can also determine that in 68.42% of cases, the following week's price action results in upside, with a median return of 2.47%.
Accounting for the volatility on Monday, a realistic target over the next three weeks — assuming that the bulls gain and maintain control of the market — is just under the $800 level.
<h2 class="wp-block-heading">Playing The Odds With Eli Lilly</h2>
Based on the market intelligence above, bold speculators may consider the 785/790 bull call spread expiring Aug. 1. This transaction involves buying the $785 call and simultaneously selling the $790 call, for a net debit paid of $255 (the most that can be lost in the trade). Should LLY stock rise through the short strike price ($790) at expiration, the maximum reward is $245, a payout of 96%.
To be sure, the 780/790 bull spread expiring on the same day offers a payout of nearly 113%. However, the net debit required is $470, which puts significantly more capital at risk for only a modest increase in payout. Therefore, the 785/790 call spread is arguably more tempting.
Either way, both transactions require LLY stock to hit or exceed $790 on Aug. 1, which empirically appears to be a reasonable target. As a baseline, the chance that a long position in LLY will be profitable on any given week is quite high at 60.29%. However, the market's response to the 6-4-D sequence amplifies the odds in favor of the bullish speculator, thus incentivizing a debit-based strategy.
The opinions and views expressed in this content are those of the individual author and do not necessarily reflect the views of Benzinga. Benzinga is not responsible for the accuracy or reliability of any information provided herein. This content is for informational purposes only and should not be misconstrued as investment advice or a recommendation to buy or sell any security. Readers are asked not to rely on the opinions or information herein, and encouraged to do their own due diligence before making investing decisions.
Read More:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/options/25/07/46253955/khc-stock-bearish-pressure-statistical-reversal">Options Corner: Why Kraft Heinz Could Flip The Script On The Bears</a></li>
</ul>
Photo: Shutterstock

RHHBY

Options Corner: Bullish Traders Eye Eli Lilly As Market Signals Hint At A Turnaround

Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) is currently experiencing a decline in its stock price, trading lower on Monday. The company&#8217;s stock has plummeted approximately 18% over the past month, reflecting recent challenges.
A significant development contributing to this decline occurred in June 2025, when Novo Nordisk A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) ended its collaboration with Hims &amp; Hers. Consequently, Hims &amp; Hers will no longer have direct access to Wegovy, Novo Nordisk&#8217;s popular GLP-1 weight-loss drug, through the <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/06/46050799/hims-hers-health-stock-is-tumbling-monday-whats-happening" rel="noreferrer noopener">NovoCare Pharmacy</a>.
Novo Nordisk stated in a press release that the termination was due to Hims &amp; Hers Health&#8217;s alleged failure to adhere to laws prohibiting mass sales of compounded drugs under the false guise of &#8220;personalization&#8221; and its use of deceptive marketing practices, which Novo Nordisk claimed disregarded patient safety.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/health-care/25/07/46269816/wegovy-zepbound-prices-drop-but-most-patients-still-cant-afford-long-term-use-coverage-is-not-the-same-as-access-says-expert" rel="noreferrer noopener">Wegovy, Zepbound Prices Drop, But Most Patients Still Can&#8217;t Afford Long-Term Use: &#8216;Coverage Is Not The Same As Access,&#8217; Says Expert</a>
This split represents the latest challenge facing Hims &amp; Hers, even as the company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030.
Hims &amp; Hers Health shares are under pressure largely because the firm sells cheaper, compounded versions of popular weight-loss drugs. Regulators typically permit compounded versions of drugs to enter the market to meet demand when there&#8217;s an official shortage of the brand-name product.
However, the FDA announced earlier this year that semaglutide, the active ingredient in Wegovy, had been removed from the drug shortage list, indicating that supply was now sufficient to meet current and projected demand. This change had a notable impact on Hims &amp; Hers.
Despite this, the company reported significant success in its GLP-1 offerings, generating over <a target="_blank" href="https://www.benzinga.com/25/05/45567780/hims-hers-health-stock-is-tumbling-thursday-whats-happening" rel="noreferrer noopener">$225 million in revenue</a> in 2024 from these products. The ongoing legal and regulatory scrutiny now centers on the legality of mass-producing compounded versions once the official shortage is declared over.
Morgan Stanley, in a Monday note, highlighted an &#8220;increased focus on both the legal and business implications that could influence the stock.&#8221; Analysts spoke with two experts to gain insight into these implications, particularly concerning Eli Lilly And Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/42783449/eli-lilly-joins-fda-lawsuit-over-compounded-obesity-drugs-seeks-swift-end-and-to-protect-its-interests" rel="noreferrer noopener">lawsuits against compounders</a>.
Analyst Craig Hettenbach says that Expert #1 cautiously advised compounding pharmacies to cease large-scale production of GLP-1 drugs once the shortage ends, acknowledging that business owners have varying levels of risk tolerance.
Expert #2 offered a more nuanced perspective, suggesting there might be a legitimate case for compounding GLP-1s under 503A for specific patient groups, even if the drugs are not individually tailored. Nevertheless, Expert #2 admitted that little legal precedent supports this view and believed that merely adding a vitamin to a GLP-1 would likely not render the product legally compliant under 503A, a common practice among some compounders.
Both experts indicated that even if the current cases are dismissed, Eli Lilly could refile with stronger arguments. Presently, the compounders are seeking dismissal of the lawsuits, contending that Eli Lilly, as a private company, cannot make certain claims that fall solely under the FDA&#8217;s jurisdiction.
The two experts discussed whether it would be helpful to ask for a preliminary injunction, a court order to stop the compounders from operating during the case. Expert #2 thinks it will be hard for Lilly to get one because the company would need to prove it&#8217;s suffering serious, irreversible harm.
Without that injunction, the compounders can keep running their businesses while the cases are ongoing. Both experts stressed that each case depends heavily on the specific facts, so gathering evidence and going through the legal process will take time. A final decision in these cases will probably take 2 to 3 years.
In light of these developments, Morgan Stanley has maintained its Equal Weight rating on Hims &amp; Hers Health, with <a target="_blank" href="https://www.benzinga.com/quote/HIMS/analyst-ratings" rel="noreferrer noopener">a price forecast of $40</a>.
Earlier in June, the company announced a significant step in its global expansion through its agreement to acquire ZAVA, a <a target="_blank" href="https://www.benzinga.com/analyst-stock-ratings/price-target/25/06/45779301/hims-hers-zava-acquisition-deal-expands-its-market-opportunity-by-52-billion-analyst" rel="noreferrer noopener">digital health platform in Europe</a>.
The strategic move will expand Hims &amp; Hers&#8217; footprint in the United Kingdom and officially launch the company into Germany, France, and Ireland, with more markets anticipated soon.
Price Action: HIMS stock is trading lower by 5.51% to $45.38 at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/guidance/25/07/46273556/molina-healthcare-says-higher-medical-cost-trends-bite-cuts-profit-guidance" target="_blank" rel="noreferrer noopener">Molina Healthcare Says Higher Medical Cost Trends Bite, Cuts Profit Guidance</a></li>
</ul>
Image by T. Schneider via Shutterstock

Hims & Hers Navigates Novo Nordisk Breakup And Compounding Lawsuits

Press Releases

Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting

Lilly to participate in Goldman Sachs 46th Annual Global Health Care Conference

Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk

VERVE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Verve Therapeutics, Inc. - VERV

Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine

Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials

Dividends

Lilly declares third-quarter 2025 dividend

Small Cap

New AI Rollouts Signal Shift From Hype to Healthcare Reality

FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease

AVAI

PLTR

VERV

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Merck & Co

Novo Nordisk

Novartis

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Regencell Bioscience Holdings Limited - Ordinary Shares

Regencell Bioscience

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Verona Pharma

Viatris

Zoetis

Guggenheim

Morgan Stanley

HSBC

Cantor Fitzgerald

Screenshot 2025-07-08 at 5.24.00 PM

ADBE

SBC Medical Group In Growth Mode: Company Gets Added To The Russell 3000 Index, Names New Chief Marketing Officer

Untitled design - 2025-03-31T165341.547

TNXP

VRTX

Tonix&#39;s Experimental Non-Opioid Analgesic Treatment For Fibromyalgia Could Start Bringing Relief Later This Year

Screenshot 2025-02-24 at 11.35.34 PM

BRTX

BioRestorative Therapies Receives FDA Fast Track Approval For BRTX-100 To Treat Chronic Lumbar Disc Disease

Screenshot 2024-11-20 at 6.30.30 PM

BioRestorative Ends Q3 In &#39;Strong&#39; Financial Position, Reports Positive Data For Its Phase 2 BRTX-100 Chronic Back Pain Trial

Screenshot 2024-09-30 at 9.13.36 PM

The Rush For Non-Addictive Painkillers To Counter The Opioid Crisis Puts Two Companies Closer To FDA Decisions

Screenshot 2024-09-10 at 4.29.40 PM

Armed With Its Patent Portfolio, BioRestorative Therapies Has Success In The Laboratory And At The Negotiating Table: Is Profitability Close Behind?

Screenshot 2024-08-22 at 5.32.58 PM

RDHL

RedHill&#39;s Opaganib Shows Diabetes And Obesity Potential With Positive In Vivo Results

Screenshot 2024-07-10 at 9.08.28 PM

AXSM

A Redux Of The Lyrica-Cymbalta Fibromyalgia War Of The 2010s May Look More Like David Vs. Goliath

Screenshot 2024-06-18 at 1.15.14 AM

BioRestorative Therapies Enters Preclinical Assessment Of Its Patented Stem-Cell Technology Prior To First-In-Human Studies

Screenshot 2024-05-16 at 5.52.00 PM

ELAB

Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries

Comments

Eli Lilly

Eli Lilly (LLY) Opzioni

Eli Lilly (NYSE:LLY) Azioni, Catena delle Opzioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO